EP Patent

EP1541585A1 — Cxcr4 antagonist and use thereof

Assigned to Biokine Therapeutics Ltd · Expires 2005-06-15 · 21y expired

What this patent protects

The present invention provides preventive and/or therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its …

USPTO Abstract

The present invention provides preventive and/or therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt.

Drugs covered by this patent

Patent Metadata

Patent number
EP1541585A1
Jurisdiction
EP
Classification
—
Expires
2005-06-15
Drug substance claim
No
Drug product claim
No
Assignee
Biokine Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.